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INTRODUCTION
Sarcopenia is an age-related loss of skeletal muscle mass that occurs at a rate of 1% to 2% per year beginning, typically, after age 50 year and progressing more rapidly and severely between late middle age and senescence. 1 In addition to age, previous research has shown that the rate of sarcopenic decline can be accelerated by concurrent comorbid conditions, lifestyle factors, and individual characteristics, including sex, genetic background, and hormone balance. 2 Sedentary lifestyles and infrequent aerobic or resistance training are particularly common contributors to sarcopenic decline in older adults. 2 For example, in 2010, only 11% of adults aged 65 years or older participated in regular aerobic or muscle-strengthening exercise, which precludes these individuals from the protective effects of these activities. 3 Moreover, 45% of women and 43% of that maximized each model's sensitivity and specifi city. A leave-one-out cross validation was used to simulate the models' performance in an independent sample. Results and Discussion: Thirty-two participants were sarcopenic, and 11 were not. Critical values for individual explanators were 21% IMAT, 68 Nm PF torque, and 441 watts of stair power. Predicted probabilities of .76 and .67 were chosen as the optimal cutoff probabilities for the model combining all 3 explanators, and the model combining PF torque and stair power, respectively. The cross-validation analysis produced an accuracy of 82.4%, using the cutoff probability of . 5 , and an accuracy of 76.5% using the cutoff of 0.76. The area under the curve for the cross validation receiver operating curve analysis was 0.82. Critical values of leg % IMAT, PF torque, and stair power can classify individuals with diabesity as sarcopenic. The results of the cross validation give us confi dence that the sample used in this study was representative of the target population, and suggests models created from this sample may perform well in externally derived data sets.
Research Report men aged 65 to 74 years are classifi ed as obese, with the onset of type 2 diabetes mellitus increasing in prevalence by 21% since 1998. 3 , 4 The combination of these 2 common conditions has been referred to as diabesity-the specifi c form of type 2 diabetes mellitus that typically develops with aging and is associated with obesity. 5 Diabesity is defi ned by several etiological characteristics that may contribute to the development of sarcopenia, including insulin resistance-which interferes with muscle anabolism and lowers the rate of muscle protein synthesis. 6 The synergistic pathophysiology of these 2 conditions may accelerate the onset and progression of sarcopenia and merits further study. 7 Sarcopenia is currently classifi ed on the basis of 3 criteria: (1) low muscle mass (defi ned using data from young individuals aged 18-39 years), when total body muscle mass falls 2 standard deviations below the mean value of a younger population assessed by dual-energy x-ray absorptiometry, or bioelectrical impedance analysis (BIA) measures, (2) reduced gait speed ( < 0.8 m/s in 4-m walk test), and (3) decreased grip strength (determinded by hand-grip dynamometry) relative to normative values based on sex, body mass index (BMI), and force. 7 , 8 These diagnostic criteria are typically used for individuals 65 years of age or older and therefore do not take into account any accelerated model of sarcopenic diabesity. Previous research has shown that individuals with type 2 diabetes and peripheral neuropathy (PN) may present with signs of sarcopenia (eg, loss of muscle strength and power, loss of physical function, and excess intermuscular adipose tissue, or IMAT accumulation) well before 65 years of age, suggesting that sarcopenia may be largely underdiagnosed in this population. 9 , 10 Traditional classifi cation criteria may also be inadequate due to the nonlinear relationship between muscle mass and strength or functional performance. Some authors suggest that the key consequence of sarcopenia is the loss of muscle strength, power, or force (dynapenia) rather than mass alone. 7 , 8 , 11 Moreover, the reliance on measures of grip strength fails to characterize muscle function in the lower extremity (particularly calf muscles), which is severely affected by type 2 diabetes + PN, and is more closely associated with physical function than thigh or upper extremity musculature. 12 Measures of lower extremity strength and functional power, therefore, may provide a more accurate basis for sarcopenic classifi cation, particularly in individuals with diabesity. In addition, because changes in muscle composition are critical to muscle quality, and excess IMAT infi ltration reduces muscle quality and performance, we hypothesized that relationships may exist between leg IMAT accumulation and sarcopenic decline, particularly in diabesity-a condition characterized by progressive IMAT accumulation and accelerated sarcopenia. 7 To our knowledge, no studies have determined critical values of leg composition, muscle strength, power, and sarcopenia in individuals with diabesity despite previous research showing that these measures are important clinical impairment indicators refl ecting common physical function defi cits in these individuals. 9 , 13 On the basis of initial evidence for accelerated sarcopenia, we hypothesize that these outcomes may hold diagnostic value in the identifi cation of sarcopenia and its contribution to functional limitation in diabesity, which will assist the clinician in designing interventions to prevent future adverse outcomes (eg, impaired mobility, falls, hospitalization, and mortality) associated with this condition. 7 , 8 , 14 Therefore, the purpose of this study was to identify critical values of the amount of leg IMAT content, plantar fl exion torque, and stair power that correctly classify obese individuals with and without type 2 diabetes and PN as sarcopenic or nonsarcopenic. This will provide clinicians with reference values of key components and constructs of sarcopenia, which can be used to derive a clearer understanding of the status of the musculoskeletal system in this population. Individuals were excluded from the study if they weighed greater than 300 pounds (equipment weight limit), presented with any recent history of illness or hospitalization (within previous 6 months), any active infection or ulceration of either foot, previous botulinum toxin injection, Ankle Brachial Index < 0.45, the presence of nonmagnetic resonance imaging (MRI) compatible implants and women who may be pregnant, a history of severe foot deformity or amputation, and the presence of any comorbidity or medications that would limit participation in physical activity testing (rheumatic disease, peripheral arterial disease, dialysis, and current cancer treatment). Each participant read and signed an institutional review boardapproved protocol that was approved by the Human Research Protection Offi ce at Washington University in St Louis, Missouri.
METHODS

Lower Extremity Sensation
Semmes-Weinstein Monofi lament and Biothesiometry testing were used to determine the presence of PN. We defi ned PN as the inability to feel the 5.07 (10-g) monofi lament on at least 1 noncallused site on the plantar aspect of either foot or the inability to perceive vibration of less than 25 volts on the biothesiometer (Biomedical Instrument, Newbury, Ohio) applied to the hallux. 15 
Body Composition
Each participant received whole-body dual-energy x-ray absorptiometry scans (Hologic Discovery GDR 1000/W, software version 12.6.2 OD; Waltham, Massachusetts) to assess regional and composite lean and fat mass in grams. Image analysis and subregion (thigh, leg, trunk, upper The black dot on the curve denotes the cutoff probability of .76 and its sensitivity and 1-specificity. The (---) line represents the ROC curve for the linear combination of PF peak torque and stair power. The black dot on the curve denotes the cutoff probability of .67 and its sensitivity and 1 − specificity. The (___) line represents chance. The area under the curve (AUC), and its significance, for each model is reported ( P < .05 indicates that classification by the model is significantly better than chance). *Note: Four participants missing data for all 3 variables, 2 missing % IMAT, 2 missing PF torque, and 1 missing stair power.
Research Report extremities) composition quantifi cation was carried out following the guidelines provided by Hologic GDR software.
Sarcopenic Index
Sarcopenic indices were calculated as described previously. 16 Appendicular lean mass (ALM) was calculated as the sum of upper and lower extremity lean mass (kg). The skeletal muscle index (SMI) was calculated as shown later. Values denoting the classifi cation for sarcopenia were implemented as outlined by Janssen et al. where scores 37% or less for men and 28% or less for women indicated classifi cation as sarcopenic. 17 
SMI =
Total body skeletal muscle mass (kg) Total body mass (kg)
Total body skeletal muscle mass
Leg Composition
Leg IMAT, subcutaneous adipose tissue, and muscle volumes (cm 3 ) were quantifi ed using T1-weighted MRI with the ankle in neutral and knee extended. Magnetic resonance imaging measurement was performed with a 3.0-T superconducting magnet with pulse sequence TE = 12 ms, TR = 1,500 ms, matrix 256 × 256, collecting both fatsaturated and non-fat-saturated images. Thirty 7-mm-thick transverse slices spanning from the tibial plateau and progressing distally were collected, and 9 slices were analyzed for fat and lean tissue volumes based on voxel brightness. 18 Volumetric assessments were made as described by Tuttle et al and Hilton et al for the anterior, lateral, and deep compartments, as well as the gastrocnemius and soleus muscles. 9 , 19 Percent IMAT tissue volume (% IMAT) was calculated from the MRI analysis as the ratio of IMAT volume to total fat volume (total = subcutaneous fat volume + IMAT volume). Tuttle et al reported less than 1% measurement error in muscle volume quantifi cation, and less than 2% error in fat volume quantifi cation with these methods, regardless of the individual muscle or compartment analyzed. 19 
Stair Vertical Power
Stair vertical power was calculated as a measure of functional performance based on the time it took to climb a standard set of 10 steps. Participants were instructed to ascend the stairs as quickly and safely as possible without the use of the handrail. Data represent the average of 2 trials. Power (watts) was calculated using the equation from Tuttle et al 13 
Leg Muscle Strength Assessment
Leg muscle strength was assessed as plantar fl exion peak torque measured at 60 deg/s using a Biodex Isokinetic Dynamometer System 3 (Shirley, New York). The ankle was placed in maximal dorsifl exion (10 ° or the maximal position achieved actively) and ended in maximal plantar fl exion (typically 30 ° -45 ° ). All participants were given 3 submaximal practice trials to familiarize them with the test movements. Plantar fl exion was repeated 3 times, with the average of the 3 trials used in the fi nal analysis.
Statistical Analysis
A chi-square test for equality of proportions was used to determine the homogeneity of sex distribution in the 3 groups for disease status (diabetes only, diabetes and PN, and obese controls). One-way analyses of variance were performed to determine group differences for age, weight, BMI, and duration of diabetes. One-way analyses of variance were also used to determine group differences in leg % IMAT, plantar fl exion peak torque, and stair power. Independent t tests were used to assess group differences between those classifi ed as sarcopenic and nonsarcopenic. An alpha level of .05 was used for signifi cance. A GamesHowell post hoc test was used in cases violating the assumption of homogeneity of variance.
To identify values of % IMAT, plantar fl exor (PF) torque, and stair power that identify the presence or absence of sarcopenia, we constructed receiver operator curves (ROCs), which were used to determine the critical value that maximized each explanator's sensitivity + specifi city. Next, we condensed these explanators into a logistic regression model to determine if their linear combination provided a greater sensitivity + specifi city than any single explanator alone. Two separate regression models were created. The fi rst combined leg % IMAT, PF torque, and stair power in the model, while the second combined only PF torque and stair power to provide an alternative for clinicians who cannot measure all 3 variables in their patients. Predicted probabilities from each model were used to create new ROCs. The predicted probability associated with the highest sensitivity + specifi city was selected as the cutoff probability for each model. The positive predictive value, negative predictive value, likelihood ratios for positive and negative test results, accuracy, and the diagnostic odds ratio (DOR) were also calculated for the model with the highest sensitivity + specifi city as described by Glas et al. 20 Briefl y, we also ran these models, using diabetes status (diabetes only, diabetes + PN, and controls) as an explanator. The addition did not add to the explanatory power of these models (see the "Results" section). For simplicity, therefore, we are reporting, in detail, the analyses using % IMAT, PF peak torque, and stair power.
To simulate classifi cation in an independent sample, a leave-one-out cross validation was performed. For each subject, the remaining participants were used to fi t the logistic regression model using % IMAT, PF torque, and stair power as explanators, which was subsequently used to classify the left-out subject as sarcopenic or nonsarcopenic. The cross-validation accuracy, sensitivity, and specifi city were calculated using the cutoff probability of .5 (which makes no assumption about the sample being representative of the population) and the optimal cutoff probability from the ROC analysis outlined earlier.
Overall regression model fi t was assessed using the Hosmer-Lemeshow Goodness of Fit Test and the potency of the model was determined using Nagelkerke's Pseudo R 2 . Area under the ROC was analyzed using the c-statistic and Akaike Information Criterion. Multicollinearity was checked using the tolerance and variance infl ation factor statistics. The leverage statistic was used to identify outliers in the data. Some participants were missing data for % IMAT, PF torque, and stair power at random: 4 were missing all 3, 2 were missing % IMAT, 2 were missing PF torque, and 1 was missing stair power. Listwise deletion was used to maximize all available data. All statistical analyses were performed in IBM SPSS Version 21 (IBM Corp, Armonk, New York) and the statistical computing software R.
RESULTS
Group Demographics
As shown in Table 1 , no group differences existed in sex, BMI, weight, or duration (years) of diabetes. The type 2 diabetes groups were younger than individuals in the control group. Monofi lament and vibration perception threshold testing confi rmed that participants in the diabetes + PN group had PN, while the other participants did not. No group differences were reported on leg % IMAT, plantar fl exion torque, and stair power.
Sarcopenic Classifi cation and Group Differences
As shown in Table 2 , 32 participants were classifi ed as sarcopenic (SP + ), and 11 were not (SP − ). Ten of 12 (83%) of the type 2 diabetes group, 16 of 21 (76%) participants in the diabetes + PN group, and 6 of 10 participants (60%) of the control group were classifi ed as sarcopenic. The SP + group displayed greater leg % IMAT than SP − and reduced stair power compared to SP − . No difference was found between SP + and SP − in plantar fl exion peak torque at 60 deg/s.
Explanatory Values of Sarcopenia
The results from preliminary ROC analyses for each single explanator are shown in Table 3 . The values providing the greatest combined sensitivity and specifi city were 21% for leg IMAT, 68 Nm for plantarfl exion torque, and 441 watts for stair power ( Figure 1 ; Table 3 ).
The logistic regression model created from the linear combination of all 3 explanators is also shown in Table 3 . The predicted probability providing the greatest sensitivity + specifi city in this model was .76, which had 80% sensitivity and 89% specifi city. This value was used as the cutoff probability. Importantly, the sensitivity + specifi city produced by the combination of all 3 explanators was greater than the sum produced by any single explanator.
The logistic regression model created from the combination of PF torque and stair power is shown in Table 3 . Research Report Abbreviations: IMAT, intermuscular adipose tissue; exp β , odds ratio; CI, confi dence interval; ROC, receiver operating characteristic curve. a The Cutoff Analysis portion of the table shows the results from the individual ROC analyses, including the value of each explanator that maximized its sensitivity and specifi city. The sensitivity and specifi city associated with the cutoff probabilities for each logistic regression model are also reported. The Logistic Regression Results (1 and 2) portions of the table contain the 2 logistic regression models, their coeffi cients, standard errors, explanator signifi cance, overall model signifi cance, and variance in the log odds of sarcopenia accounted for by each model (Nagelkerke's R 2 ). The regression equations, created from the regression coeffi cients, demonstrate how values for % IMAT, PF Torque, and Stair Power can be used to calculate a predicted probability ( P ) of having sarcopenia. b P < .05. Abbreviation: IMAT, intermuscular adipose tissue. a P < .05, 2-tailed, independent t test.
The predicted probability providing the greatest sensitivity + specifi city was .67, which had an 80% sensitivity and a 73% specifi city. The sensitivity + specifi city of this model was higher than PF torque or stair power alone but was less than % leg IMAT alone or the linear regression using all 3 explanators ( Table 3 ) . The linear regression model combining all 3 explanators produced a likelihood ratio of a positive test of 7.92 (indicating that a predicted probability > 0.76 is ∼ 8 times more likely if the individual has sarcopenia), a likelihood ratio of a negative test of 0.23, a positive predictive value of 95% (the probability of an individual with a predicted probability > .76 having sarcopenia), and a negative predictive value of 64% (the probability of an individual with a predicted probability < .76 not having sarcopenia). The model accurately diagnosed 80% of participants and had a DOR of 34.2, indicating that the odds of a correct classifi cation of sarcopenia are 34.2 times higher than the odds of an incorrect classifi cation when using this explanatory model. The addition of diabetes status to the models changed the R 2 value by only 0.9% and did not affect the model signifi cance, optimal cutoff value from ROC analyses, or explanatory ability.
The cross-validation analysis produced an accuracy of 82.4%, a sensitivity of 92%, and a specifi city of 60% using the cutoff probability of .5. Using the cutoff probability of .76, the cross validation had an accuracy of 76.5%, a sensitivity of 75%, and a specifi city of 80%. The area under the curve for the cross-validation ROC analysis was .82 ( P < .05).
DISCUSSION
This study is the fi rst to report critical values of leg fat, PF muscle strength, and physical function as potential explanators of sarcopenia in individuals with diabesity. We demonstrated that all 3 explanators can be used to delineate the presence of sarcopenia, but the regression model using all 3 explanators produced the highest sensitivity (80%) + specifi city (89%), suggesting that these measures are most effective when used together. The DOR (34.2) of this model, and the difference between sarcopenic and non-sarcopenic individuals on these measures, lends further support for their diagnostic utility.
When implementing the logistic regression equations clinically, many combinations of individual explanatory values produce the cutoff probability (.76 for the model using all 3 explanators or .67 for the model using PF torque and stair power). Our results indicate that having a predicted probability of sarcopenia above the cutoff means that the individual likely has sarcopenia, which may guide the clinician's plan of care (ie, to select interventions targeting sarcopenia).
The leave-one-out cross validation simulated the performance of the regression model combining all 3 explanators when applied to a new sample from the same population. At cutoff probabilities of .5 and .76, the cross validation correctly classifi ed 82% and 76.5% of subjects respectively, and produced a sensitivity + specifi city greater than 150, which is very close to model's performance in the derivation data set. This gives us confi dence that the sample used in this study was representative of the target population, and suggests that models created from this sample may perform well in externally derived data sets.
Obese individuals with type 2 diabetes are particularly susceptible to the acceleration of sarcopenia due to the coincident impairments in metabolism underlying these conditions. Both sarcopenia and diabesity are associated with mitochondrial dysfunction, low-grade systemic infl ammation, insulin resistance, growth hormone and IGF-1 decrements, immobility, reduced physical activity, and sensorimotor neuron loss in the case of diabetes + PN. 19 , 21-24 Baumgartner et al 25 reported that it took less time for obese, sarcopenic individuals to develop limitations in IADLs than individuals with sarcopenia or obesity alone. Our results support this idea, with individuals with type 2 diabetes as young as 38 years classifi ed as sarcopenic on the SMI.
The incipient impairment of these explanators may be leg IMAT deposition, which is thought to accumulate in response to a diabesity-related reduction in muscle oxidative capacity. 7 Mitochondrial dysfunction from IMAT accumulation may lead to myocyte apoptosis, which could be exacerbated by impairments in skeletal muscle autophagy in type 2 diabetes. 26 , 27 Diabetic denervation may further accelerate the rate of apoptosis and the loss of lean muscle volume, with IMAT accumulating in space previously occupied by healthy muscle fi bers. 14 Intermuscular adipose tissue accumulation is also inversely correlated with growth hormone secretion and insulin sensitivity and may impart lipotoxic effects and release proinfl ammatory cytokines that contribute to declining force production, muscle quality, and reduced mobility. 26 , 28 Our cutoff analysis suggests that when IMAT comprises 21% of an individual's total leg fat, they likely have sarcopenia. We speculate that this value represents a threshold of muscle structural resilience, suggesting that IMAT accumulation of 21% or greater may disrupt muscle structure (fascicle arrangement, pennation angle, sarcomeres in-series) and elicit sarcopenic impairment. 15 , 23 Bittel et al 29 showed that for every 1% increase in leg % IMAT, there is an accompanying 0.1-point reduction in the physical performance test (PPT) score (consisting of 9 functional tasks scored 0-36, with lower scores meaning worse performance). King et al 30 found that a 2.4-point reduction in PPT score constituted a clinically meaningful change in physical function. Therefore, accumulation of 24% IMAT corresponds to a 2.4-point reduction in PPT score, which coincides closely with our 21% IMAT threshold (ie, 21% IMAT = 2.1 point reduction in PPT scores).
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These results suggest that clinicians should assess for sarcopenia in individuals with diabesity and consider treatment plans that mitigate its progression. Resistance training may be a cornerstone of these plans, as it improves muscle quality and function, enhances motor recruitment, increases lean body mass, and is the most effective treatment for sarcopenia. 39 Eves and Plotnikoff have reported that only 12% of North Americans with type 2 diabetes perform regular resistance exercise. 40 This disengagement potentially contributes to sarcopenia and mandates further investigation into alternative means of resistance training.
This study has limitations. While the diagnostic linear regression model produced high diagnostic utility during cross validation, these models require external validation in a separate sample from the same target population. We did not obtain serum or tissue (muscle, adipose) samples to determine infl ammatory status, protein composition, presence of proteolysis, hormone levels, insulin sensitivity, muscle structural status, or mitochondrial content and oxidative function in relation to our selected explanatory values. Thus, our deductions are merely empirical and warrant further investigation. A larger sample size would provide more defi nitive sarcopenic classifi cation with these explanatory values.
CONCLUSION
Based on the results of this study, the explanatory values for IMAT, PF peak torque, and stair power can help physical therapists and rehabilitation specialists identify sarcopenia's contribution to muscle and physical dysfunction in diabesity. These measures refl ect the pattern of impairment commonly associated with this condition, offering a customized alternative to traditional sarcopenic classifi cation systems, which may not be optimally suited for this clinical population.
We acknowledge that the use of MRI to quantify leg IMAT is not (yet) a diagnostic tool that is readily available for most clinicians. However, based on the results of this study and previous investigations, 9 , 13 , 19 IMAT represents a signifi cant structural impairment that appears in multiple musculoskeletal, neurologic, and pulmonary conditions and affects all levels of physical function. 24 , 31 Leg % IMAT, alone, produced a higher sensitivity + specifi city than the linear combination of PF torque and stair power. Furthermore, the regression model combining all 3 explanators, including leg % IMAT, had the highest sensitivity + specifi city, confi rming its importance in the identifi cation of sarcopenia.
In addition to leg IMAT, we also determined explanatory values for physical function (stair power) to give clinicians a more readily useful means of assessing and determining progression to sarcopenia. The ability to climb stairs strongly correlates with other measures of functional disability and decline in medical status. 32 Our stair power threshold value indicates that along the continuum of progressive metabolic and morphological impairments in diabesity, individuals who produce less than 441 watts of power while ascending a fl ight of stairs are very likely to have sarcopenia. While this is the fi rst study to provide a threshold value for stair power in this population, similar research coincides with these fi ndings.
Shimada et al 33 found that among older (average age of 80 years) community-dwelling adults, leg extensor power of 484 watts differentiated men who reported diffi culty with ascending stairs from those who did not ( < 484 watts equated with self-reported diffi culty). This critical value may represent individuals more affected by sarcopenia and has notable similarity to our own threshold value.
Ankle PF strength (a measure of muscle performance), in addition to its role in climbing stairs, is a central component in the successful completion of many functional activities, including ambulation and rising from a chair. 32 , 34 , 35 We found that PF torque of 68 Nm helps differentiate sarcopenic from nonsarcopenic diabesity-a population that expresses a litany of metabolic and physiological impairments of the leg. 3 , 19 Specifi cally, this cutoff may indicate an increased risk of abnormal gait (including declines in gait speed and step length) or falls. 12 , 36 , 37 Reduced torque from the gastrocnemius and soleus may diminish one's ability to slow the forward progression of the body about the ankle when recovering from a perturbation. 37 Indeed, Landi et al 38 reported that individuals who are sarcopenic are at 3.23 times higher risk for falls than individuals without sarcopenia regardless of age, gender, BMI, or secondary impairments (eg, diabetes, stroke). We acknowledge that not all clinics will have access to isokinetic dynamometry. Like MRI, we encourage clinicians to work with the patient's physician and the care center to obtain these measurements before creating the treatment plan.
